Analyst Price Targets — ACRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 10:44 am | — | UBS | $10.00 | $3.93 | TheFly | Aclaris Therapeutics initiated with an Outperform at Oppenheimer |
| January 30, 2026 12:09 pm | Adam Vogel | Craig-Hallum | $10.00 | $3.43 | TheFly | Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy |
| November 19, 2024 7:35 am | Julian Harrison | BTIG | $8.00 | $3.14 | StreetInsider | BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 19, 2024 7:34 am | Roger Song | Jefferies | $7.00 | $3.14 | StreetInsider | Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 6, 2024 5:46 pm | Alex Thompson | Stifel Nicolaus | $3.00 | $2.28 | StreetInsider | Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel |
| December 1, 2022 5:35 am | — | Goldman Sachs | $25.00 | $15.22 | Benzinga | Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25 |
Latest News for ACRS
Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,017,767 shares, an increase of 49.4% from the March 15th total of 4,697,214 shares. Based on an average trading volume of 1,880,039 shares, the short-interest ratio
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat…
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its…
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK)…
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACRS.
U.S. House Trading
No House trades found for ACRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.